US FDA approves Pfizer's drug for rare bleeding disorder
Adds analyst estimates in paragraph 6, trial details in paragraph 8, and other treatments in paragraph 5, 10 and 11
By Sruthi Narasimha Chari and Christy Santhosh
Oct 11 (Reuters) -The U.S. Food and Drug Administration approved Pfizer's PFE.N once-a-week injection for the two main types of a rare bleeding disorder called hemophilia, the company said on Friday.
The drug, Hympavzi, is given under the skin through an auto-injector pen to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older.
The disorder primarily affects men and causes spontaneous and potentially severe bleeding after injuries or surgery. It impacts an estimated 33,000 men in the United States, according to government data.
Hympavzi is Pfizer's second hemophilia treatment to receive FDA approval this year after the agency greenlit its hemophilia B gene therapy Beqvez in April.
Other existing treatments include gene therapies such as those made by Australia's CSL CSL.AX and BioMarin Pharmaceutical BMRN.O.
Analysts expect sales of Hympavzi to reach $300 million by 2030, according to estimates compiled by LSEG.
"Hympavzi aims to reduce the current treatment burden by meeting an important need for these patients, including many who have required frequent, time-consuming intravenous treatment infusion regimens," said Suchitra Acharya, director of the bleeding disorders program at Cohen Children's Medical Center.
The approval was based on a late-stage study in 116 hemophilia A or B patients, where the drug showed superiority to standard-of-care treatment with a 92% reduction in bleeding episodes after 12 months.
The drug is approved for patients without antibodies that stop the production of the blood-clotting proteins called factor VIII or factor IX.
Other experimental hemophilia drugs include fitusiran by partners Sanofi SASY.PA and Alnylam Pharmaceuticals ALNY.O, and Novo Nordisk's NOVOb.CO concizumab.
Pfizer is also developing a gene therapy with Sangamo Therapeutics SGMO.O for the treatment of hemophilia A.
Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Vijay Kishore
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
